sc13gza
 

     
 
OMB APPROVAL
  
 
OMB Number: 3235-0145
  
 
Expires: February 28, 2006
  
 
Estimated average burden hours per response...11
  
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

ANTIGENICS INC
(Name of Issuer)
COMMON STOCK, $0.01 PAR VALUE
(Title of Class of Securities)
037032-10-9
(CUSIP Number)
December 31, 2005
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     o Rule 13d-1(c)

     þ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 

 

                     
CUSIP No.
  
037032-10-9 

 

           
1   NAMES OF REPORTING PERSONS:
Garo H. Armen
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   þ
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  United States of America
       
  5   SOLE VOTING POWER:
     
NUMBER OF   1,011,291(1)
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   11,489,274(2)
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   1,011,291(1)
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    11,489,274(2)
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  12,500,565
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  26.8%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN

(1) Includes 1,006,291 shares issuable upon exercise of options to purchase Antigenics Inc. common stock.

(2) Consists of (i) 11,154,274 shares held by Antigenics Holdings LLC, of which Dr. Armen is the Chief Executive Officer, Chairman of the Board of Managers and a member and (ii) 335,000 shares held by Armen Partners LP, of which Dr. Armen is the General Partner.

 

                     
CUSIP No.
  
037032-10-9 

 

           
1   NAMES OF REPORTING PERSONS:
Antigenics Holdings LLC (13-4060592)
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   þ
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  United States of America
       
  5   SOLE VOTING POWER:
     
NUMBER OF   11,154,274
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY  
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   11,154,274
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
   
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  11,154,274
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  24.5%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  OO - Limited Liability Company

 

                     
CUSIP No.
  
037032-10-9 

 

           
1   NAMES OF REPORTING PERSONS:
Armen Partners LP (22-2964842)
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   þ
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  United States of America
       
  5   SOLE VOTING POWER:
     
NUMBER OF   335,000
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY  
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   335,000
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
   
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  335,000
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.7%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN - Limited Partnership

 

Item 1.
Item 1(a) Name of issuer:   Antigenics Inc.
Item 1(b) Address of issuer’s principal executive offices:   630 Fifth Avenue, Ste 2100
New York, NY 10111
Item 2.
2(a) Name of person filing:   Garo H. Armen
Antigenics Holdings LLC
Armen Partners LP
2(b) Address or principal business office or, if none, residence: For each reporting person:   c/o Antigenics Inc.
630 Fifth Avenue, Ste 2100
New York, NY 10111
2(c) Citizenship: Garo H. Armen is a citizen of the United States of America. Antigenics Holdings LLC is a Delaware limited liability company. Armen Partners LP is a Delaware limited partnership.
2(d) Title of class of securities: Common Stock, $0.01 par value
2(e) CUSIP No.: 037032-10-9
Item 3.
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
     a.   [ ] Broker or dealer registered under Section 15 of the Act.
     b.   [ ] Bank as defined in Section 3(a)(6) of the Act.
     c.   [ ] Insurance company as defined in Section 3(a)(19) of the Act.
     d.   [ ] Investment company registered under Section 8 of the Investment Company Act of 1940.
     e.   [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     f.   [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     g.   [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

 

     h.   [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     i.   [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     j.   [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Not Applicable
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
  a.   Amount beneficially owned: See Box 9 on cover pages
 
  b.   Percent of class: See Box 11 on cover pages
 
  c.   Number of shares as to which such person has:
  i.   Sole power to vote or to direct the vote: See Box 5 on cover pages
 
  ii.   Shared power to vote or to direct the vote: See box 6 on cover pages
 
  iii.   Sole power to dispose or to direct the disposition of: See Box 7 on cover pages
 
  iv.   Shared power to dispose or to direct the disposition of: See Box 8 on cover pages
Item 5. Ownership of 5 Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].
Item 6. Ownership of More than 5 Percent on Behalf of Another Person
     Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     Not applicable

 

 

Item 8. Identification and Classification of Members of the Group
     See Exhibit 2
Item 9. Notice of Dissolution of Group
     Not applicable
Item 10. Certifications
     Not applicable

 

 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2006
/s/ Garo H. Armen
Garo H. Armen
Antigenics Holdings LLC
By: /s/ Garo H. Armen
Name: Garo H. Armen
Title: Manager          
Armen Partners LP
By: /s/ Garo H. Armen
Name: Garo H. Armen
Title: Manager          

 

 

EXHIBIT INDEX TO SCHEDULE 13G
EXHIBIT 1
Agreement as to Joint Filing of Schedule 13G
EXHIBIT 2
List of all members of group

 

 

EXHIBIT 1
Each of the undersigned hereby affirms that he, she or it is individually eligible to use Schedule 13G and agrees that this Schedule 13G is filed on his, her or its behalf.
Dated: February 13, 2006
/s/ Garo H. Armen
Garo H. Armen
Antigenics Holdings LLC
By: /s/ Garo H. Armen
Name: Garo H. Armen
Title: Manager          
Armen Partners LP
By: /s/ Garo H. Armen
Name: Garo H. Armen
Title: Manager          

 

 

EXHIBIT 2
Garo H. Armen
Antigenics Holdings LLC
Armen Partners LP